ES2673583T3 - Anticuerpo contra fibrina insoluble - Google Patents
Anticuerpo contra fibrina insoluble Download PDFInfo
- Publication number
- ES2673583T3 ES2673583T3 ES14757745.6T ES14757745T ES2673583T3 ES 2673583 T3 ES2673583 T3 ES 2673583T3 ES 14757745 T ES14757745 T ES 14757745T ES 2673583 T3 ES2673583 T3 ES 2673583T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- fibrinogen
- chain
- fibrin
- present disclosure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013039625 | 2013-02-28 | ||
| JP2013039625 | 2013-02-28 | ||
| PCT/JP2014/054925 WO2014133093A1 (ja) | 2013-02-28 | 2014-02-27 | 不溶性フィブリンに対する抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2673583T3 true ES2673583T3 (es) | 2018-06-22 |
Family
ID=51428352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14757745.6T Active ES2673583T3 (es) | 2013-02-28 | 2014-02-27 | Anticuerpo contra fibrina insoluble |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9429584B2 (enExample) |
| EP (2) | EP3339327A3 (enExample) |
| JP (2) | JP6490574B2 (enExample) |
| ES (1) | ES2673583T3 (enExample) |
| WO (1) | WO2014133093A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016167227A1 (ja) * | 2015-04-13 | 2016-10-20 | 国立研究開発法人国立がん研究センター | 不溶性フィブリンに対する抗体 |
| US9623118B2 (en) | 2015-09-01 | 2017-04-18 | Immunwork Inc. | Multi-arm linker constructs for treating pathological blood clots |
| MY195529A (en) | 2016-11-18 | 2023-01-30 | Astellas Pharma Inc | Novel Anti-Human MUC1 Antibody Fab Fragment |
| IL324632A (en) * | 2016-12-01 | 2026-01-01 | Regeneron Pharma | Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging |
| CN110650974B (zh) | 2017-02-10 | 2024-04-19 | 瑞泽恩制药公司 | 用于免疫-pet成像的放射性标记的抗-lag3抗体 |
| CN110582514B (zh) * | 2017-05-02 | 2024-03-01 | 国立研究开发法人国立癌症研究中心 | 纤溶酶可切割的抗不溶性纤维蛋白的抗体与药物的偶联物 |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| MY197688A (en) | 2017-07-24 | 2023-07-05 | Regeneron Pharma | Anti-cd8 antibodies and uses thereof |
| WO2019221269A1 (ja) | 2018-05-17 | 2019-11-21 | アステラス製薬株式会社 | 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体 |
| US12157768B2 (en) | 2018-09-17 | 2024-12-03 | Icahn School Of Medicine At Mount Sinai | Anti-LILRB2 antibodies and methods of use thereof |
| MY205764A (en) | 2018-10-10 | 2024-11-12 | Astellas Pharma Inc | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex |
| JP7750828B2 (ja) | 2019-09-16 | 2025-10-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質 |
| WO2021163989A1 (en) * | 2020-02-21 | 2021-08-26 | Yinnuolai Biotech Ltd. | Anti-baff receptor antibodies and uses thereof |
| KR20220161374A (ko) | 2020-03-31 | 2022-12-06 | 국립연구개발법인 고쿠리츠간켄큐센터 | 피브린에 결합하는 항체 및 당해 항체를 포함하는 의약 조성물 |
| AU2021246398A1 (en) * | 2020-03-31 | 2022-11-03 | National Cancer Center | Fusion protein suitable for dissolving fibrin clot, and pharmaceutical composition containing said fusion protein |
| EP3916009B1 (en) * | 2020-05-26 | 2023-06-28 | Sartorius Lab Instruments GmbH & Co. KG | Recombinant proteins based on fibrinogen |
| TW202405178A (zh) | 2022-04-08 | 2024-02-01 | 日商凜研究所股份有限公司 | 與纖維蛋白結合的抗體及含有該抗體的纖維蛋白溶解性蛋白質以及含有該蛋白質的醫藥製劑 |
| CN118240085B (zh) * | 2022-10-08 | 2025-05-09 | 东莞市朋志生物科技有限公司 | 抗纤维蛋白降解产物抗体、检测纤维蛋白降解产物的试剂和试剂盒 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4916070A (en) | 1986-04-14 | 1990-04-10 | The General Hospital Corporation | Fibrin-specific antibodies and method of screening for the antibodies |
| US5120834A (en) * | 1988-06-13 | 1992-06-09 | American Biogenetic Sciences, Inc. | Fibrin-specific monoclonal antibody |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH11206387A (ja) | 1991-08-28 | 1999-08-03 | Genpharm Internatl Inc | 異種免疫グロブリンを作る方法及びそのためのトランスジェニックマウス |
| US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| CA2194907A1 (en) | 1994-07-13 | 1996-02-01 | Kouji Matsushima | Reshaped human antibody against human interleukin-8 |
| KR19990008197A (ko) | 1995-04-28 | 1999-01-25 | 레이몬드 엠. 위티 | 면역화된 제노마우스 유래의 인체 항체 |
| JPH08301900A (ja) | 1995-04-28 | 1996-11-19 | Shima Kenkyusho:Kk | 可溶性フィブリン複合体に対するモノクローナル抗体 |
| JPH09104700A (ja) | 1995-10-09 | 1997-04-22 | Bio Rinkusu Kk | 抗ヒト可溶性フィブリン抗体及びそれを用いた免疫学的測定法 |
| JP2001354700A (ja) | 2000-06-12 | 2001-12-25 | Bio Links Kk | モノクロ−ナル抗体及びヒトフィブリン分解産物の測定方法 |
| ES2376454T3 (es) | 2000-12-22 | 2012-03-14 | Grad, Carole, Legal Representative Of Howard, Kaplan | Librer�?as de expresión en fago de fragmentos vh humanos. |
| CN1531554A (zh) | 2001-06-26 | 2004-09-22 | ��������ҽѧ����˾ | 血纤维蛋白d-二聚体片段特异性的、来源于dd-3b6/22的人源化抗体 |
| JP5222521B2 (ja) | 2004-12-28 | 2013-06-26 | 積水メディカル株式会社 | 抗ヒト可溶性フィブリンモノクローナル抗体の製造方法 |
| JP4088328B2 (ja) | 2004-12-28 | 2008-05-21 | 第一化学薬品株式会社 | 抗ヒト可溶性フィブリンモノクローナル抗体及び当該抗体を用いる免疫学的測定方法 |
| MX2008007477A (es) * | 2005-12-12 | 2008-09-03 | Ac Immune Sa | Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas. |
| DK2514823T3 (en) * | 2006-03-03 | 2018-07-23 | Promis Neurosciences Inc | Methods and compositions for treating and detecting failed SOD1-mediated diseases |
| JP5013378B2 (ja) | 2007-02-05 | 2012-08-29 | 国立大学法人大阪大学 | 新規ヘキサトリエン−β−カルボニル化合物 |
| WO2010055950A1 (ja) | 2008-11-17 | 2010-05-20 | 財団法人ヒューマンサイエンス振興財団 | 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療 |
| JP5805363B2 (ja) * | 2009-06-26 | 2015-11-04 | 和興フィルタテクノロジー株式会社 | 可溶性凝集体、免疫寛容誘導剤及びその製造方法 |
| JP2012000072A (ja) | 2010-06-18 | 2012-01-05 | Japan Health Science Foundation | 新規な抗フィブリン抗体 |
| AR086250A1 (es) * | 2011-05-05 | 2013-11-27 | Hoffmann La Roche | Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo |
-
2014
- 2014-02-27 JP JP2015503025A patent/JP6490574B2/ja active Active
- 2014-02-27 US US14/770,864 patent/US9429584B2/en active Active
- 2014-02-27 EP EP18155006.2A patent/EP3339327A3/en not_active Withdrawn
- 2014-02-27 WO PCT/JP2014/054925 patent/WO2014133093A1/ja not_active Ceased
- 2014-02-27 ES ES14757745.6T patent/ES2673583T3/es active Active
- 2014-02-27 EP EP14757745.6A patent/EP2963059B1/en active Active
-
2018
- 2018-07-23 JP JP2018137861A patent/JP7012360B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2963059A4 (en) | 2017-03-22 |
| WO2014133093A1 (ja) | 2014-09-04 |
| JPWO2014133093A1 (ja) | 2017-02-02 |
| EP2963059B1 (en) | 2018-04-04 |
| US20160011217A1 (en) | 2016-01-14 |
| JP7012360B2 (ja) | 2022-02-14 |
| JP2018193386A (ja) | 2018-12-06 |
| JP6490574B2 (ja) | 2019-03-27 |
| US9429584B2 (en) | 2016-08-30 |
| EP3339327A3 (en) | 2018-09-19 |
| EP3339327A2 (en) | 2018-06-27 |
| EP2963059A1 (en) | 2016-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7012360B2 (ja) | 不溶性フィブリンに対する抗体 | |
| US8101713B2 (en) | Prostate cancer diagnosis and treatment | |
| ES2657246T3 (es) | Procedimientos para tratar el cáncer pancreático | |
| ES2720594T3 (es) | Anticuerpos anti-fXI y métodos de uso | |
| BR112016011025B1 (pt) | Polipeptídeos anticorpo com especificidade de ligação para calicreina-2 humana (hk2), composição farmacêutica que os compreende e molécula de ácido nucleico | |
| BRPI0908737B1 (pt) | Anticorpo, seu uso e método de diagnóstico de carcinoma hepatocelular | |
| US20230338589A1 (en) | In vivo immunoimaging of interferon-gamma | |
| Guan et al. | Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo | |
| WO2025040093A1 (zh) | 靶向gpc3的分子探针以及用途 | |
| ES2639227T3 (es) | Anticuerpos anti S100A7 para el tratamiento y diagnóstico de cáncer | |
| TW201842938A (zh) | 可藉由胞漿素切斷之抗不溶性纖維蛋白抗體與藥物之複合體 | |
| WO2011158973A1 (ja) | 新規な抗フィブリン抗体 | |
| ES2709549T3 (es) | Métodos y composiciones farmacéuticas para el tratamiento de carcinomas hepatocelulares | |
| US6264949B1 (en) | Noninvasive agents for diagnosis and prognosis of the progression of fibrosis | |
| CN103201291A (zh) | 抗单链iv型胶原多肽抗体和包含其的用于诊断、预防或治疗肿瘤的药物或药剂 | |
| WO2016167227A1 (ja) | 不溶性フィブリンに対する抗体 | |
| CN115461462B (zh) | 与纤维蛋白结合的抗体及含有该抗体的药物组合物 | |
| EP3728301A2 (en) | Antibodies to centrin-1, methods of making, and uses thereof | |
| Matsumura | Cancer and blood coagulation | |
| WO2013141092A1 (ja) | 癌転移マーカー及びそれを用いた癌転移の診断方法 | |
| BR122020023278B1 (pt) | Uso de um polipeptídeo anticorpo para a fabricação de um medicamento para o tratamento e/ou diagnóstico de câncer de próstata |